Average Co-Inventor Count = 7.19
ph-index = 11
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Ambrx, Inc. (28 from 113 patents)
2. The Scripps Research Institute (3 from 1,187 patents)
3. Elanco US Inc. (2 from 42 patents)
4. Eli Lilly and Company (4,447 patents)
31 patents:
1. 11993637 - Modified FGF-21 polypeptides with non-naturally encoded amino acids
2. 11786578 - Modified relaxin polypeptides and their uses
3. 11542310 - Modified bovine G-CSF polypeptides and their uses
4. 11439710 - Nucleic acids encoding modified relaxin polypeptides
5. 11420999 - Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
6. 11311605 - Methods of treating heart failure and fibrotic disorders using modified relaxin polypeptides
7. 10961291 - Modified FGF-21 polypeptides and their uses
8. 10954270 - Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
9. 10751391 - Methods of treatment using modified relaxin polypeptides comprising a non-naturally encoded amino acid
10. 10702588 - Modified relaxin polypeptides comprising a non-naturally encoded amino acid in the A chain
11. 10377805 - Modified FGF-21 polypeptides comprising non-naturally encoding amino acids and their uses
12. 10253083 - Therapeutic uses of modified relaxin polypeptides
13. 10138283 - Modified bovine G-CSF polypeptides and their uses
14. 9975936 - Nucleic acids encoding modified FGF-21 polypeptides comprising non-naturally occurring amino acids
15. 9962450 - Method of treating heart failure with modified relaxin polypeptides